# About Medicinal GHK-Cu: An Independent Research Field Guide

> About Medicinal GHK-Cu — an independent editorial project that surveys and summarizes the peer-reviewed GHK-Cu copper-peptide literature. Not a clinic, not a vendor, no medical advice.

Who maintains this field guide, what it is, and the line it does not cross.

## What this project is

Medicinal GHK-Cu is an independent editorial project that publishes summaries of the peer-reviewed research literature on GHK-Cu, the copper-binding tripeptide glycyl-L-histidyl-L-lysine. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The approach is the one a field naturalist takes to a territory: survey what is there, label it accurately, mark the boundaries, and cite where every observation came from. The GHK-Cu literature is unusually well-suited to that treatment. The compound was first isolated from human plasma in 1973, it is endogenous rather than synthetic, and its published record now spans five decades across skin, hair, wound-repair, the gut and the brain [6]. That breadth is exactly why a careful index is worth maintaining.

## What the name means — and does not

The word 'medicinal' in this site's name is editorial framing, not a service claim. It describes the lens — a heritage-apothecary, research-survey posture toward a copper peptide with a long therapeutic-research history — not an offer of treatment, consultation, or prescription. This site does not diagnose, prescribe, dispense, or advise. There are no doctors, pharmacists, or clinical staff behind it, real or implied.

We hold one editorial standard above all others: every quantitative claim is tied to a published source, and the gaps are marked as plainly as the findings. GHK-Cu has a strong preclinical and topical-cosmetic record and a thin controlled-human one, and this guide states both halves without smoothing the difference. Where a result belongs to a combination formulation rather than pure GHK-Cu, or to a rodent model rather than a human trial, we say so.

## How the literature is weighed

Findings are surveyed by evidence class, not by enthusiasm. A picomolar collagen dose-response measured in human fibroblasts [1] carries different weight than a community-circulated dosing protocol with no peer-reviewed basis. A placebo-controlled hair-count trial [4] is reported with its formulation caveat intact. A genome-wide expression figure is reported alongside the honest note that the often-quoted '~4,000 genes' number is an extrapolation [2].

We also flag a structural feature of this field: a large share of the foundational GHK-Cu mechanistic and review literature originates from a single investigator and colleagues, which is why independent replication of the broader gene-expression and anti-aging claims matters and is noted where relevant [6]. None of this is a verdict for or against the compound. It is a map of what the studies have measured and where the trail currently ends.

---

A 1970s field guide to the GHK-Cu copper-peptide literature — five decades of skin, hair, wound-repair and gene-expression findings surveyed and pinned to their sources, with no clinic at the trailhead and nothing here to sell.